October 27, 2020 P&T Meeting Update
Due to the current COVID-19 pandemic, the October 27th Pharmacy and Therapeutics Committee meeting will be held virtually. Pharmaceutical and trade representatives wishing to attend are advised of the following:
- Registration opens 30 days prior to meeting date and will close one (1) day before the meeting date. Registration is currently closed until Sept. 25.
- Pharma and trade reps wishing to attend are REQUIRED to register in order to attend by clicking on the registration link located on this page.
- Once registered, pharma and trade reps will be emailed audio conference information either they day before or the day of the meeting to the registrant’s email address. As a reminder, please utilize your company provided email address (please do not use Gmail, Yahoo, etc.). Please check your email the day of the event (including spam folders) for conference dial in information.
- When registering as speaker concerning a drug, please indicate the drug(s) listed on the P&T agenda that you wish to provide testimony. Additional drugs may not be added the day of the meeting.
- If you have questions pertaining to the agenda, please contact Change Healthcare (contact information provided below).
The Mississippi Division of Medicaid’s Pharmacy and Therapeutics (P&T) Committee is comprised of twelve participating physicians, nurse practitioners, and practicing pharmacists who are active MS Medicaid providers and in good standing with their representative organizations. The P&T Committee is an advisory panel who conducts in-depth clinical evaluations and recommends appropriate drugs for preferred status on DOM’s Preferred Drug List (PDL) and/or drugs for prior authorization. Drugs and drug classes are evaluated for their safety, efficacy, and overall cost value and the committee will make subsequent recommendations to the Executive Director regarding prior authorization criteria for these drugs and classes.
The decision of the committee regarding any limitations to be imposed on any drug or its use for a specified indication shall be based on sound clinical evidence found in labeling, drug compendia, and peer reviewed clinical literature pertaining to use of the drug in the relevant population.
P&T Committee Meeting Information
The P&T Committee meets four (4) times annually. Registration opens 30 days prior to the meeting date. Due to limited seating availability, no more than two (2) representatives per pharmaceutical organization may register/attend. Medicaid’s Pharmacy & Therapeutics Committee meeting schedule:
Feb. 18(cancelled), May 12, Aug. 11, and Oct. 27
P&T Committee Meeting Resources
NOTE: Registration is required for all pharmaceutical industry and advocacy representatives to be able to attend P&T Committee meetings.
- Industry, DOM Public Comment 2017
- P&T Committee Members
- Letter to Governmental Affairs Representatives
- Mississippi Pharmacy Program Frequently Asked Questions
P&T Committee Meeting Minutes and Agendas | Archive of Meeting Minutes and Agendas
|Date||P&T Meeting Minutes||P&T Agenda|
|Aug. 11, 2020||Minutes||Agenda|
|Oct. 22, 2019||Minutes||Agenda|
|Aug. 13, 2019||Minutes||Agenda|
|May 7, 2019||Minutes||Agenda|
|Feb. 12, 2019||Minutes||Agenda|
Preferred Drug List (PDL)
The preferred drug list is a medication list recommended to the Division of Medicaid (DOM) by the P&T Committee and approved by the Executive Director of the DOM. Drugs designated as preferred have been selected for their efficaciousness, clinical significance, cost effectiveness and safety for Medicaid beneficiaries. Most generic agents are preferred, do not require prior authorization and may not be individually listed. Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
Medicaid-covered drugs noted as “non-preferred” will continue to be available through the prior authorization process. A three-day emergency supply of prior-authorized drugs can be dispensed by a pharmacy until authorization is completed.
The PDL only addresses certain drug classes. Drugs which have historically been covered by Medicaid and are not listed on the Preferred Drug List will continue to be covered. Some drug classes will not be reviewed for preferred status because of no and/or limited cost savings, if the class is all and/or mostly generic, or if there is low utilization in that class. Be advised that DOM may opt to include or delete drug classes from PDL review in the future.
New drugs introduced into the marketplace in therapeutic classes that have been reviewed will be considered non-preferred until the annual review of the particular therapeutic class.
Important Information for Drug Manufacturers
Change Healthcare (CHC), has been awarded the contract for Preferred Drug List Maintenance and Supplemental Rebate Program for the Mississippi Division of Medicaid (DOM) effective July 1, 2016.
P.O. Box 1090
Augusta, ME 04332-1090
Industry Information Requests
Industry representatives with clinical inquires related to drugs listed on the Preferred Drug List may contact the Division’s clinical contractor, Change Healthcare (CHC). The primary contact at CHS for Mississippi Medicaid is:
Rusty Hailey, Pharm.D., D.Ph., MBA, FAMCP
P&T Committee Contacts
Please route inquiries regarding the P&T Committee to the Bureau of Pharmacy:
Phone: (601) 359-5253